ANVISA approves new Covid-19 vaccine
ANVISA has approved the registration of the Covid-19 vaccine (recombinant) from Zalika Farmacêutica Ltda.
A monovalent immunizer with recombinant protein S antigen and saponin adjuvant, increasing antibody production.
ELS helps from drug development to registration in Brazil, Latin America and Europe.
local ELS consultant or via email info@elssolutions.pt
ontact your